Regent Pacific’s Deep Longevity Sets Sights on the U.S. with Q1 2026 Market Entry

HONG KONG, December 2, 2025 — Hong Kong–based investment group Regent Pacific Group Limited (HKEX: 0575) has announced that its subsidiary Deep Longevity, Inc. will enter the United States market in the first quarter of 2026, marking a significant milestone for the fast-advancing longevity science and AI-healthtech company.

Deep Longevity, a pioneer in explainable AI-driven aging clocks and a global leader in biological age assessment technologies, is preparing to scale its solutions into what is currently the world’s largest and fastest-growing wellness market, valued at over US$6.8 trillion. The expansion aims to reach millions of consumers seeking evidence-based, personalised longevity insights while unlocking partnerships across the healthcare and wellness ecosystem.

AI-Powered “Aging Clocks” Enter the World’s Biggest Wellness Market

Known for its multimodal, clinically validated aging clocks—including BloodAge, MindAge, BiometricAge, EpigeneticAge, and the soon-to-launch FaceAge—Deep Longevity provides multi-dimensional biological age assessments that go far beyond measuring chronological age. The company’s technology taps into biomarkers, epigenetics, psychological profiling, and biometric data to help physicians, employers, insurers, and wellness providers better understand aging trajectories, slow down age-related decline, and extend health-span.

Deep Longevity’s portfolio also reflects its foundations as a scientific and technological innovator. The company has published numerous peer-reviewed studies and holds multiple patents for its AI-driven systems that track aging at the molecular, cellular, tissue, organ, physiological, and psychological levels. Its Longevity-as-a-Service (LaaS) solution—built to integrate these data streams—offers healthcare professionals and consumers a single, comprehensive measure of biological aging.

To accelerate its entry into the market, Deep Longevity will establish a U.S.-based sales organisation, beginning with two new hires starting 1 January 2026. This team will lead partnership development with longevity platforms, diagnostic labs, wellness and preventive health clinics, corporate wellness programs, insurers, employers, and premium health services. Initial market penetration will focus on the southeastern United States, covering states such as Florida, Georgia, Tennessee, the Carolinas, Virginia, West Virginia, Louisiana, Alabama, Arkansas and Kentucky.

“Entering the U.S. is the most important milestone in Deep Longevity’s journey,” said Deepankar Nayak, CEO of Deep Longevity. “Our aging clocks are already trusted by leading clinics and platforms worldwide. With a dedicated American team, we are ready to bring personalised, preventive longevity care to millions of people and capture a significant share of this US$6.8 trillion market opportunity.”

Deep Longevity is wholly owned by Regent Pacific Group, a diversified Hong Kong–based investment group with strong holdings in healthcare, wellness and life sciences. Regent Pacific has maintained a consistent investment track record and has returned nearly US$298 million to shareholders since its listing in 1997. The group’s backing has allowed Deep Longevity to accelerate the development of its AI-driven systems for longevity medicine, enabling physicians worldwide to make more informed decisions on interventions designed to slow or reverse biological aging.

Positioning for Global Leadership in Longevity Science

With global demand for personalised health optimisation rising, Deep Longevity’s entrance into the U.S. positions it at the forefront of a rapidly commercialising sector. As aging and preventive health solutions gain mainstream traction, its AI-based aging clocks—spanning everything from blood markers to facial analytics—offer a scientific foundation for physicians and wellness programs looking to deliver targeted interventions.

The company’s continued push into North America underscores both its global ambitions and the increasing relevance of longevity-focused AI as populations seek to extend not just lifespan, but healthy years of life.